Tailing Biopharmaceutical Jiangsu

Jiangsu Tailing Biopharmaceutical is a clinical-stage biotechnology company based in the China Medical City of Taizhou, specializing in the development of high-end biologics and vaccines. The company focuses on leveraging advanced recombinant protein expression systems and large-scale cell culture technologies to produce essential medicines. Its lead product candidates include a human diploid cell rabies vaccine and recombinant human serum albumin, both designed to offer improved safety and purity over traditional plasma-derived or animal-based products. Tailing Biopharmaceutical operates integrated R&D and GMP-compliant manufacturing facilities to support its transition toward commercialization. The company aims to address critical healthcare needs in infectious diseases and blood-related disorders within the Chinese and global markets.